<DOC>
	<DOC>NCT01363947</DOC>
	<brief_summary>Study DNB4987g is a Phase I, multicenter, open label, dose-escalation study of DNIB0600A administered as a single agent by intravenous (IV) infusion to patients with non-squamous NSCLC or non-mucinous, platinum resistant ovarian cancer.</brief_summary>
	<brief_title>Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Histologic documentation of incurable, locally advanced or metastatic disease that has failed prior chemotherapy and for which no standard therapy exists, including the following: nonsquamous NSCLC or nonmucinous and platinumresistant ovarian cancer Availability and willingness to provide an adequate archival sample of tumor Measurable disease For fertile men or women of childbearing potential, documented willingness to use a highly effective means of contraception Antitumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy within 4 weeks prior to study treatment Major surgical procedure within 4 weeks prior to study treatment Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infections of the nail beds) Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis Untreated or active central nervous system (CNS) metastases Requirement for supplemental oxygen to carry out activities of daily living Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications Evidence of significant uncontrolled concomitant diseases, such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disorders; or a serious nonhealing wound or fracture Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>